All partners will receive the highest recognition for their support of EBJIS.
For more information about the partnership packages, exhibition and other sponsorship opportunities, please download the Partner and Exhibitor information Booklet in the left column.
There will be other branding opportunitites available than the ones mentioned in the booklet. By booking one of the branding options, you have the golden opportunity to increase your company awareness and brand recognition at the conference.
For further information or to make a booking, please contact the EBJIS2020 Sales & Exhibition Manager
Mona Ibsgaard: email@example.com
Tel.: +45 7020 0305
Sign-up for the EBJIS Conference Newsletter and keep in touch with the latest news here
Confirmed Partners and Exhibitors
At Biocomposites, we are distinct in that our team of specialists is singularly focused on the development of innovative calcium compounds for surgical use.
With over 30 years’ experience and an unrivalled dedication to quality, the products we research, engineer and manufacture are at the forefront of calcium technology.
We are proud to be driving improved outcomes across a wide range of clinical applications, in musculoskeletal infection, trauma, spine and sports injuries, for surgeons and patients alike.
BONESUPPORT™ is an orthobiologic company specializing in the development of innovative injectable bone graft substitutes that remodel into bone within 6 to 12 months. Used in more than 40,000 patients, and includes the only CE marked injectable antibiotic eluting bone graft substitutes; CERAMENT® G with gentamicin, and CERAMENT® V with vancomycin.
The Company’s research and development is focused on extending the use of its CERAMENT technology into further indications via the incorporation of additional drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote & protect bone growth.
Heraeus Medical stands for delivering value to the patient, the healthcare professional and the healthcare system through innovation and evidence based medicine in Implant Fixation, Infection Management and regenerative treatments for bone, cartilage and soft tissue. Over the years the company built up extensive experience in the field of therapeutic support for PJI with local antibiotics and is a reliable and committed partner in all aspects that deal with the management of musculoskeletal infections.
InfectoPharm is a family-owned medium-sized company located in area of Frankfurt. Since 1988 the company has been developing pharmaceuticals for children and therapeutic options for difficult-to-treat infections. Today, Infectopharm`s pediatric portfolio covers OTC and prescription-only pharmaceuticals for indications such as infectious and respiratory diseases, dermatology, and gastroenterology. The hospital anti-infectives portfolio includes antibiotics for difficult-to-treat conditions such as nosocomial infections and cystic fibrosis.
Lyfstone AS provides the orthopaedic health care professionals with a point-of-care test for ruling out Prosthetic Joint Infection (PJI) by measuring the levels of Calprotectin in synovial fluid. Rapidly ruling out infection creates the opportunity for same-day diagnostics for evidence-based decisions and patient flow.
Lyfstone® Calprotectin for synovial fluid, is a quantitative, accurate, cost-saving and efficient tool providing results within 15 minutes. The test is a diagnostic aid for screening of suspected PJI patients.